Ken Griffin Cidara Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$0.64 - $0.92 $1,728 - $2,484	2,700 New	2,700 $2,000
Q3 2023 Nov 14, 2023	SELL	$0.77 - $1.16 $1,386 - $2,088	-1,800 Reduced 12.0%	13,200 $12,000
Q2 2023 Aug 14, 2023	BUY	$1.01 - $1.42 $7,474 - $10,508	7,400 Added 97.37%	15,000 $16,000
Q1 2023 May 15, 2023	SELL	$0.75 - $1.98 $26,925 - $71,082	-35,900 Reduced 82.53%	7,600 $9,000
Q4 2022 Feb 14, 2023	BUY	$0.48 - $13.08 $11,280 - $307,380	23,500 Added 117.5%	43,500 $33,000
Q3 2022 Nov 14, 2022	BUY	$0.45 - $13.0 $9,000 - $260,000	20,000 New	20,000 $13,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $753M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.